SEC Tracker
Get the app

Enanta Pharmaceuticals ENTA

Enanta Pharmaceuticals: quarterly report for the quarter ended Mar 31, 2022

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Enanta Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  2. Galectin Therapeutics GALT public float $109M, Jun 30, 2025
  3. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  4. Cartesian Therapeutics RNAC public float $109M, Jun 30, 2025
  5. Caribou Biosciences CRBU public float $113M, Jun 30, 2025